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Introduction: India is in the process of a major epidemiological transition towards
non-communicable diseases. Cardiovascular disease (CVD) is the leading cause of death
in women in India. Predisposing independent risk factors include pregnancy-related
conditions, e.g., hypertensive disorders of pregnancy (HDP) and gestational diabetes
(GDM) - also associated with significant perinatal mortality and morbidity. Early
identification, referral and management of pregnant women at increased risk of future
CVD may offer opportunities for prevention. In rural India, Community Health Workers
(CHWs) provide most antenatal and postnatal care. Innovative solutions are required to
address integrated care for rural women during transitions between antenatal, postnatal
and general health services. The George Institute’s SMARThealth Programme has shown
that CHWs in rural India screening non-pregnant adults for cardiovascular risk, using a
decision support system, is feasible. Building on this, we developed a targeted training
programme for CHWs and a complex system-level intervention that uses mobile clinical
decision support for CHWs and primary care doctors to screen high-risk pregnant
women. In addition to addressing HDP and GDM, the intervention also screens for
anaemia in pregnancy.
Methods/Design: A pilot study will be undertaken in two diverse rural districts of India:
Jhajjar (Haryana) and Guntur (Andhra Pradesh). Two Primary Health Centre clusters will
be randomised to intervention or control groups at each study site. The primary objective
of this pilot study is to explore the feasibility and acceptability of the SMARThealth
Pregnancy intervention. Secondary objectives are to estimate: (a) prevalence rates of
moderate to severe anaemia, HDPs and GDM at the study sites; (b) referral and follow-up
rates, and (c) mean haemoglobin and blood pressure values at the routine 6 week
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postnatal visit. A process evaluation will be conducted to explore the acceptability of the
SMARThealth Pregnancy intervention for pregnant women and healthcare workers using
qualitative methods.
Discussion: It is anticipated that the findings of this pilot study will help determine the
feasibility and acceptability of the SMARThealth Pregnancy intervention, and highlight
how the intervention might be further developed for evaluation in a larger, cluster
randomised controlled trial.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT03968952.
Keywords: high-risk pregnancy, gestational diabetes, hypertensive disorders of pregnancy, pre-eclampsia,
anaemia in pregnancy, cardiometabolic disorders
INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of death
in women in India (1), and the prevalence of cardiometabolic
disorders is rising (2). Two-thirds of the Indian population live in
rural areas (3), where lack of health education and access to health
services make women less likely to seek care for cardiometabolic
disorders. Pregnancy-related conditions including hypertensive
disorders of pregnancy (HDP) and gestational diabetes mellitus
(GDM) carry independent risks for future CVD in women (4–
8). Early identification, referral and management of pregnant
women at increased risk of future cardiometabolic disorders
may offer opportunities for prevention. Innovative solutions are
required to address the needs of rural women, particularly during
the transitions between antenatal and postpartum care and adult
health services.
Community Health Workers (CHWs) known as Auxiliary
Nurse Midwives (ANMs) and Accredited Social Health Activists
(ASHAs) in rural India, provide the majority of antenatal and
postnatal care. Task-sharing with CHWs and use of digital
and mhealth interventions in rural India have been shown
to facilitate the detection, referral and management of non-
communicable diseases (NCDs) in non-pregnant adults (9, 10),
and HDP in pregnant women (11). There is, however, a paucity
of high-quality evidence to guide the postnatal management
of women following high-risk pregnancy, including those with
multi-morbidity in low-resource settings. Most randomised trials
in the postnatal period have focused on neonatal outcomes (12,
13), rather than focus on women - who remain at risk of both
immediate complications and future cardiometabolic disorders.
We conducted an in-depth contextual study in rural areas
of two diverse states in India (Haryana and Andhra Pradesh)
exploring women’s and healthcare professionals’ understanding
of high-risk conditions in pregnancy and their sequalae during
and after pregnancy (14). The study highlighted that anaemia
in pregnancy was considered as a priority area for high-
risk pregnant women by healthcare workers and government
officials. We further identified the need for education to improve
awareness and institution of standardised screening to identify
women with pregnancies complicated by HDP and GDM, and
institute a regular follow up schedule. This contextual study
provided the foundation for the theory-informed development
of a complex intervention (SMARThealth Pregnancy), consisting
of mobile clinical decision support, and a targeted education and
training programme for CHWs. The focus of the SMARThealth
Pregnancy intervention is to address improvement of women’s
postpartum health, through provision of clinical decision support
and training to CHWs in relation to three priority areas:
Anaemia, HDP and GDM, during the crucial transition between
antenatal and postnatal care, and general health services. The
intervention aims to connect pregnant women identified to be at
high risk of future cardiometabolic disorders to the Government
of India’s non-communicable disease (NCD) programme for
ongoing, life-long follow-up. The intervention is informed by
behaviour change theory (15–17) and the MRC framework for
complex interventions (18).
The underlying hypothesis of this pilot study is that
the SMARThealth Pregnancy intervention can improve the
detection, referral and management of anaemia, HDP, and
GDM during the antenatal and postnatal period; and improve
knowledge of CHWs to enable them to manage high-risk
pregnancies in two areas of rural India. We aim to develop
sufficient evidence to design a larger trial that would test the
effectiveness of the intervention on an adequate scale.
Aims and Objectives
The aim of this pilot study is to assess address the feasibility
and acceptability of the SMARThealth Pregnancy intervention;
determine whether the intervention integrates within the existing
health system, and identify any unintended consequences.
The primary objectives of the study are to:
1. Determine whether it is feasible to recruit clusters of Primary
Health Centres (PHCs) and pregnant women to the study.
2. Evaluate the intervention’s acceptability to end-users
(including CHWs and pregnant/postpartum women), to
ensure the proposed intervention is feasible and optimised for
a definitive trial.
The secondary objectives include:
1. Determine prevalence rates of moderate to severe anaemia,
HDP and GDM in pregnant women at the study sites.
2. Determine referral rates for these conditions.
3. Determine loss to follow-up rates up to 6 weeks postpartum.
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4. Assess the extent to which the intervention was delivered as
planned by CHWs (intervention fidelity) by looking at the
completeness of the entries into the mHealth tablet and the
timing of these entries.
5. Collection of clinical outcome data, including mean blood
pressure (BP) and haemoglobin (Hb) levels at 6–10 weeks
postpartum, to inform a sample size calculation and intraclass
correlation coefficient (ICC) required for a larger cluster
randomised controlled trial (cRCT).
6. To assess CHWs’ (ANMs and ASHAs) knowledge retention
following a targeted educational programme on anaemia in
pregnancy, HDP and GDM, and their long-term sequelae.
METHODS
Study Design
This is a prospective, parallel, unblinded, cluster randomised
controlled pilot study (cRCT). The design was chosen to model
and assess study practises including participant recruitment,
retention and fidelity of intervention delivery to inform the
design of a future definitive trial. The study protocol was
developed using the CONSORT 2010 statement extension for
randomised pilot and feasibility trials (19). As part of the
evaluation process, a qualitative sub-study will be conducted
with participants and healthcare workers. This pilot trial was
registered with ClinicalTrials.gov (NCT03968952) (20).
Study Setting
The study will be conducted in rural districts of two states in
India: Jhajjar (Haryana) and Guntur (Andhra Pradesh). Haryana
is a state in northern India, whose history of significant gender
inequity (21), has improved over the last decade due to targeted
legislation and policies, as well as community-based action
groups. Andhra Pradesh is a state in south-eastern India with
high rates of diabetes and hypertension in the adult population
(22). The two states are geographically and culturally diverse,
with unique languages, cuisine and practises. The maternal
mortality ratio is 101/100,000 births in Haryana, and 74/100,000
births in Andhra Pradesh (23). In the National Family Health
Survey IV (24), total prevalence of hypertension and diabetes in
women of reproductive age was 10.1% in Andhra Pradesh, and
9.2% in Haryana. Prevalence of raised blood sugar indicative of
diabetes in women of reproductive age in Andhra Pradesh and
Haryana was 13.1 and 6.6%, respectively (24).
Sampling
A list of PHCs in each district will be compiled using data from
Government of India State websites (25, 26). The PHCs will be
stratified by geographic region and population size (each PHC to
serve a population above 30,000) to include: up to eight primary
care doctors (two at each PHC cluster), up to 20 ANMs (five at
each cluster), and 80 ASHAs (20 at each cluster). The villages
selected under each intervention and control PHC will be non-
contiguous to avoid contamination. Each PHC will be assessed
for eligibility (see below). Consent for the PHC and its staff to
participate in the study will be obtained from the administrative
TABLE 1 | Summary of inclusion criteria for the study.
Inclusion criteria
• Primary Health Centres (PHCs) serving a population of 30,000 people or more,
in either the: (a) Jhajjar district of Haryana or (b) Guntur district of Andhra
Pradesh.
• Primary care doctors working at the participating PHCs, in either (a) Jhajjar
district of Haryana or (b) Guntur district of Andhra Pradesh.
• Community Health Workers (ANMs and ASHAs) working in partnership with the
participating PHCs, in either (a) Jhajjar district of Haryana or (b) Guntur district
of Andhra Pradesh.
• Pregnant women above the age of 18 years (adults) living within the villages in
the catchment area of the PHCs participating in the study, in either (a) Jhajjar
district of Haryana or (b) Guntur district of Andhra Pradesh.
*PHCs and participants not meeting the above criteria will be excluded from the
study
lead at each eligible PHC prior to randomisation. Please see
Table 1 for the study inclusion criteria.
Randomisation
Randomisation will be at the PHC cluster level, as individual
randomisation would not be possible due to potential
contamination. Four PHCs (including the villages affiliated
to each PHC) will be allocated centrally to the SMARThealth
Pregnancy intervention or control group (enhanced standard
care), using a simple random number generator. This process
will be overseen by a statistician at The George Institute for
Global Health (TGIGH), blinded to the PHCs.
Participants
We will recruit 200 pregnant women (50 in each of the four
PHC clusters) from the two districts. Participants will be ≥18
years old (adults), between 28 and 36 weeks’ gestation, and
followed up until and including 6 weeks postpartum. The last
trimester of pregnancy was chosen to recruit participants as the
contextual study (14) revealed women migrated to their mother’s
homes prior to delivery. We wanted to ensure these women
were connected to health services after migration and received
postpartum follow-up. After discussion with a statistician at
TGIGH (LB), four clusters from two different districts recruiting
a total of 200 pregnant women were considered pragmatic to
provide rich feasibility data, as well as early estimates of clinical
outcomes. As the focus of this pilot study is to assess the feasibility
and acceptability of conducting a definitive trial, no formal
sample size calculation was undertaken.
Recruitment and Consent
Eligible pregnant women will be identified by the ANM during
their standard antenatal care visits. The ANM will inform the
locally-based research assistant from TGIGH, India, of eligible
participants. The research assistant will then obtain informed
consent to participate in the study.
Women in the intervention group will be asked to consent to
having their BP and Hb measured by an ASHA at three time
points during: (a) the last trimester of pregnancy (between 28
and 36 weeks gestation); (b) week 1 postpartum and (c) week 6
postpartum. They will also consent to sharing their antenatal care
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handheld record containing their demographic details, medical
and obstetric history, and details of all their previous BP and
Hb readings. In addition, they will consent to having their BP
and Hb measured at home by an independent member of the
research team at the baseline of the study, and after the final 6
week postpartum visit (see Figure 1).
Women in the control group will be asked to consent to
sharing their antenatal care handheld record, containing their
demographic details, medical and obstetric history, and details
of all their previous BP and Hb readings from their antenatal
visits. In addition, they will consent to having their BP and Hb
measured at home by an independent member of the research
team at the baseline of the study, and after their routine 6 week
postpartum visit. Individual consent will be sought from CHWs
and doctors prior to interviews and FGDs.
THE SMARTHEALTH PREGNANCY
INTERVENTION
The SMARThealth Pregnancy intervention includes
two components:
1. A targeted educational and training component for CHWs on
anaemia in pregnancy, HDP and GDM.
2. An mHealth platform providing clinical decision support and
lifestyle advice for ASHAs and primary care doctors.
The intervention will be delivered in three stages: (1) Education
and Training; (2) Delivery of the mHealth Intervention and (3)
End of study assessment (see Figure 2).
Stage 1: Education and Training
A train the trainers programme has been developed for all study
staff on the importance of identifying women with a high-risk
pregnancy; detecting anaemia, HDP and GDM antenatal and
postnatally, and the impact of these conditions on the life-long
health of women. The programme also outlines the delivery of
the standardised training for CHWs.
The training curriculum for CHWs has been designed to
build upon existing CHW training on high-risk pregnancies,
and cover key learning objectives in relation to the importance
of identification of high-risk pregnant women, with a focus on
detection, referral and management of HDP, GDM, and anaemia
in pregnancy according to established clinical guidelines (27–
31). CHWs will also be taught how to use the SMARThealth
Pregnancy mHealth mobile tablet, and provided information on
what to do if the technology does not work properly. They will
additionally learn the following skills:
1. Measuring BP using the CRADLE VSA Blood Pressure
Monitor (APEC, UK) (32) and interpreting the readings. The
CRADLE device is a low-cost semi-automated BP device,
specifically designed for low resource settings, charged using
an android phone charger, and has been used by CHWs in
India (31).
2. Measuring Hb using the handheld TrueHb Hemometer©
(Wrig nanosystems Pvt. Ltd., 2020) (33) and interpretation
of readings.
3. Communication of findings and concerns by ASHA to
ANM/primary care doctor, and skills in handover of care
between health professionals.
Training will be delivered to ASHAs and ANMs in a series of five
participatory learning sessions each of 3-h duration conducted
over two and a half days, with a 1-day face-to-face refresher
training session after 4 weeks. In between the two training
sessions, there will be “hand-holding” in the field by the local
study field team, to ensure the ASHAs feel confident using the
blood pressure device, haemoglobinometer and the tablet device
(see below).
The curriculum for primary care doctors will cover the same
areas as for CHWs, however the delivery will be over a half-day
of one-to-one training, assuming a degree of baseline knowledge
on both educational and training components.
Stage 2: The SMARThealth Pregnancy
mHealth Platform
The SMARThealth Pregnancy mHealth platform is a
smartphone-based application, using an Android operating
system, on a seven inch mobile tablet. The application is
multi-faceted and includes provision of clinical decision support
for ASHAs and primary care doctors regarding interpretation
of BP, Hb and blood sugar measurements, grading of severity
and appropriate referral information using established clinical
guidelines (27–31). Mobile tablets will be provided to ASHAs
working in the villages, and to the primary care doctor at the
corresponding PHC.
In addition to standard antenatal and postnatal visits, ASHAs
in the intervention group will visit the pregnant woman enrolled
in the study at home, and perform BP readings, and take a
finger-prick Hb test at three different time points:
1) Once during the last trimester of pregnancy between 28 and
36 weeks’ gestation.
2) At 1–2 weeks postpartum
3) At 6 weeks postpartum
The SMARThealth Pregnancy mHealth platform will have
options for the ASHAs to enter the input measurements to
generate recommendations based on the woman’s history, BP,
Hb and blood glucose readings, which will be confidentially
uploaded to a patient record using Open MRS software (34) and
synchronise to a sister-tablet held by the primary care doctor at
the local PHC. All recommendations are based on established
country-specific clinical guidelines. Women will be referred to
the doctor at the local PHC via the mHealth platform, and
provided with a paper referral card. Although women cannot
be compelled to see the primary care doctor, they will however
be encouraged to attend the PHC after each ASHA visit. The
ASHA will accompany the woman for the visit to the primary
care doctor or to secondary care as per current standard practise.
Through the SMARThealth Pregnancy mHealth platform,
the primary care doctor will be able to note if the woman is
anaemic (and the severity), hypertensive, and/or screen-positive
for GDM. The primary care doctor will be guided to repeat these
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FIGURE 1 | Participant flowchart of pilot study.
readings if the patient attends the PHC, with access to guideline-
based decision support for anaemia, hypertension and GDM as
to the next steps in management/and or referral to secondary
care. Priority patients (identified to have high-risk pregnancy
conditions, and/or outstanding investigations), will have a red
traffic light alert and be automatically placed at the top of the
priority list when the SMARThealth Pregnancy application is
launched on the ASHA and primary care doctor tablets.
Postnatal visits take the same course as the antenatal visit,
except the history-taking will involve details of the birth and
labour (Postpartum:Week 1 visit), and any further complications
(Postpartum: Week 6 visit).
To ensure quality assurance for intervention practises, regular
field visits and observations of ASHAs and primary care doctors
will be made by the research team and project managers at each
study site to ensure compliance to study procedures and the
fidelity of the intervention practises. In addition, data collected
through the mHealth tablets will be used to monitor visits made
and completed by ASHAs and primary care doctors.
Control Group
The control group will receive enhanced standard antenatal
and postnatal care, involving: An awareness programme for
pregnant women, CHWs and primary care doctors, conducted
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FIGURE 2 | Stages in SMARThealth pregnancy study.
during an established village health and nutrition day camp (held
monthly), at the villages within the control group PHC cluster.
The community and health professionals will receive information
on the high-risk conditions of anaemia in pregnancy, HDP and
GDM as part of the awareness programme.
Stage 3: End of Study Assessment
After the final 6 week postpartum ASHA visit, an independent
researcher (not blinded to the intervention) will visit the woman
at home and complete an end of study questionnaire, and record
BP and Hb readings independently in both the intervention and
control groups. This visit will be conducted between 6 and 10
weeks postpartum allowing for convenience of study participants.
They will also document if women in the control group had
received a 6 week postpartum visit from their ASHA/ANM.
Primary and Secondary Outcomes
Primary outcomes relating to feasibility of the
intervention include:
1. Recruitment rates of pregnant participants per cluster
per month.
2. Retention rates of participants at 6 weeks postpartum.
3. An overview of the acceptability of the SMARThealth
Pregnancy intervention using a qualitative sub-study.
Secondary outcomes include:
1. Prevalence rates of moderate to severe anaemia, HDP and
GDM diagnosed in the study sites.
2. Assessment of fidelity of the intervention by:
i. Proportion of visits conducted in line with
intervention protocol.
ii. Proportion of visits completed by ASHA (including
measurement of Hb and BP) at visits during: (a)
third trimester, (b) 1–2 weeks postpartum, (c) 6 weeks
postpartum, in the intervention group.
iii. Proportion of pregnant women detected, referred,
managed, and followed-up, with moderate to severe
anaemia, HDP or GDM.
3. Proportion of women receiving their 6 week postnatal check
by the ASHA.
4. Clinical outcomes: Mean Hb and mean BP at 6 week
postpartum visit.
Process Evaluation
As part of the process evaluation, a qualitative sub-study
will be conducted to explore the acceptability of the
SMARThealth pregnancy intervention to healthcare workers
and pregnant/postpartum women; whether the intervention
components had been delivered to plan; how the intervention
integrates into existing health system practises; any unintended
consequences; and to understand how to improve and refine
the intervention and its implementation. A purposive sample of
participants including pregnant/postpartum women, CHWs and
primary care doctors from the intervention groups at each study
site will be invited to share their experiences of the SMARThealth
Pregnancy intervention in focus group discussions (FGDs)
and/or in-depth interviews (IDIs). We aim to conduct up to four
FGDs involving pregnant/postpartum women; up to four FGDs
with CHW, and up to four IDIs with primary care doctors across
both study sites. Interviews and focus groups will be conducted
with CHWs and pregnant/postpartum women at regular
intervals during the study: after they have conducted/received
visit 1, visit 2 and visit 3; to assess acceptability of each visit
to participants as the study progresses. IDIs will be held with
doctors at the end of the study to minimise inconvenience due
to the workforce constraints affecting primary care doctors in
rural areas. Qualitative data from the process evaluation will be
analysed using a framework approach (35) using nVIVO QSR©
software to facilitate the organisation of the data into codes
and categories.
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Statistical Analysis
Analysis of the pilot study will focus on descriptive statistics
rather than formal hypothesis testing. Quantitative data relating
to the detection, referral, treatment and follow-up rates of
pregnant women with (a) anaemia; (b) HDPs; and (c) GDM
will be collected for the intervention group. Data relating to
the number of pregnant women participating in the study, will
allow the proportions of women with these conditions, receiving
treatment and follow-up care to be calculated. The proportion
of women having their 6 week postpartum visit will also be
calculated in both groups. The feasibility of the recruitment
strategy and the retention of participants throughout the study
will be summarised. Statistical analysis will be conducted at the
end of the study once all data collection is completed.
Even though this is a pilot study, we will explore for any
differences between the intervention and treatment groups,
using an intention-to-treat analysis. Mean differences in 6 week
postpartum Hb and BP will be calculated using an analysis
of covariance adjusted for the baseline outcome value and for
clustering by site. All statistical analysis will be performed using
the Statistical Programme for Social Sciences (SPSS©).
To inform the sample size calculation for a larger cluster
randomised controlled trial, we will calculate the standard
deviation around the mean Hb and BP values at 6 weeks
postpartum as well as the intra-cluster correlation (ICC) and its
95% confidence interval. ICC estimates will be derived from a
mixed-effect model using SAS software©.
Data Monitoring and Confidentiality
Data generated through the SMARThealth Pregnancy mHealth
platform will be securely uploaded (using Open MRS v1.9) and
stored on a secure server at The George Institute, India. All data
will be de-identified and anonymised. Data will be monitored for
quality and completeness by the programme manager at regular
intervals as it is uploaded to the server. All data will be stored
and handled in accordance with the principles of the 1998 Data
Protection Act.
Ethical Approval and Trial Oversight
Ethical approval for the study has been obtained from the Oxford
Tropical Research Ethics Committee (OxTREC reference:
22-19) and the George Institute India Ethics Committee
(Reference: 010/2019).
The trial steering committee will oversee the study and
be responsible for participant safety. Regular operation group
meetings and field team meetings will be held with relevant
members of the team. The pilot study sponsor is the University
of Oxford, and the study will be funded by the George Institute
for Global Health India, and the Medical Research Council
(individual MRC fellowship to SN: MR/R017182/1).
DISCUSSION
The importance of addressing the rising burden of
cardiometabolic disorders in women in rapidly developing
low- and middle-income countries, such as India, is becoming
a priority. Early detection of at-risk women during pregnancy
and implementing appropriate interventions might be one
way to alleviate this burden (36). Studies have shown that
almost half of Indian women with GDM, convert to type
2 diabetes within 5 years postpartum (37, 38), providing a
key window for prevention. HDP are also associated with an
increased risk of future CVD (39, 40), although the trajectory
is longer. There is uncertainty as to the best time to counsel
women regarding their long-term health, and what evidence-
based strategies might be successfully implemented following
pregnancy in high-risk women. Balancing the long term needs
of women and their healthcare priorities during pregnancy
(such as anaemia), requires careful thought. The SMARThealth
Pregnancy intervention seeks to introduce concepts of integrated
life-long women’s health into standard antenatal and postnatal
care, whilst strengthening existing practices. There is evidence
to suggest that involving CHWs in women’s health is feasible
(41) and can improve antenatal care practises (42, 43), although
no CHW-led intervention studies focusing exclusively on
high-risk pregnancy have to date shown an improvement on
clinical endpoints (43, 44). Additionally, the lack of evidence
regarding the effectiveness of mHealth solutions in improving
clinical outcomes in LMIC settings is an important barrier to
their wide use (45). This pilot cRCT seeks to provide sufficient
feasibility data to enable refinement of the SMARThealth
Pregnancy mHealth intervention and to model future trial
processes. The results of this study will build upon the existing
evidence for CHW-led community-based digital interventions
for women, as well as extending this evidence to include ongoing
postpartum follow-up; connecting high-risk women to local
NCD programmes, and using antenatal care as a window for
engagement with the health system. The study will further
identify important factors for strengthening primary care in
rural India in relation to providing an integrated life-course
approach to women’s health.
CONCLUSION
This protocol has outlined the aims and objectives of a pilot
cRCT of a complex intervention, with a detailed overview of
the intervention components and delivery. The pilot study will
impact on the decision to conduct a larger cRCT and will
help refine the intervention and trial practises. It will add
to the evidence for the feasibility of early detection of high-
risk women, and CHW-led community-level interventions and
strategies for addressing pregnancy-related conditions and life-
long women’s health.
AUTHOR CONTRIBUTIONS
SN designed the pilot study protocol and wrote the first draft of
the article. SK, VJ, RN, LH, LB, ER, VA, DP, and JH contributed
to editing the draft for publication. All authors contributed to the
article and approved the submitted version.
Frontiers in Global Women’s Health | www.frontiersin.org 7 May 2021 | Volume 2 | Article 620759
Nagraj et al. SMARThealth Pregnancy: Feasibility and Acceptability
FUNDING
SN was supported by an MRC Clinical Research Training
Fellowship (MR/R017182/1). LH was based in The Healthcare
Improvement Studies Institute (THIS Institute), University
of Cambridge. THIS Institute is supported by the Health
Foundation, an independent charity committed to bringing
about better health and healthcare for people in the UK.
REFERENCES
1. Norton R, Peters S, Jha V, Kennedy S, Woodward M. Women’s Health: A
New Global Agenda. Oxford Martin Policy Paper. Available online at: https://
www.oxfordmartin.ox.ac.uk/downloads/briefings/women%27s-health.pdf
(accessed February 07, 2019).
2. Prabhakaran D, Jeemon P, Sharma M, Roth GA, Johnson C, Harikrishnan S,
et al. The changing patterns of cardiovascular diseases and their risk factors
in the states of India: the global burden of disease study 1990–2016. Lancet
Global Health. (2018) 6:E1339–51. doi: 10.1016/S2214-109X(18)30407-8
3. The World Bank Data 2019. Available online at: https://data.worldbank.org/
indicator/SP.RUR.TOTL.ZS?locations=IN (accessed October 16, 2020).
4. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk
of cardiovascular disease and cancer in later life: systematic review and
meta-analysis. BMJ. (2007) 335:974. doi: 10.1136/bmj.39335.385301.BE
5. Skjaerven R, Wilcox AJ, Klungsoyr K, Irgens LM, Vikse BE, Vatten
LJ, et al. Cardiovascular mortality after pre-eclampsia in one child
mothers: prospective, population based cohort study. BMJ. (2012)
345:e7677. doi: 10.1136/bmj.e7677
6. Tobias DK, Stuart JJ, Li S, Chavarro J, Rimm EB, Rich-Edwards J, et al.
Association of history of gestational diabetes with long-term cardiovascular
disease risk in a large prospective cohort of US women. JAMA Intern Med.
(2017) 177:1735–42. doi: 10.1001/jamainternmed.2017.2790
7. Brown MC, Best KE, Pearce MS, Waugh J, Robson SC, Bell R. Cardiovascular
disease risk in women with pre-eclampsia: systematic review and meta-
analysis. Eur J Epidemiol. (2013) 28:1–19. doi: 10.1007/s10654-013-9762-6
8. McDonald SD,Malinowski A, Zhou Q, Yusuf S, Devereaux PJ. Cardiovascular
sequelae of preeclampsia/eclampsia: a systematic review and meta-
analyses. Am Heart J. (2008) 156:918–30. doi: 10.1016/j.ahj.2008.
06.042
9. He J, Irazola V, Mills KT, Poggio R, Beratarrechea A, Dolan J, et al. Effect
of a community health worker–led multicomponent intervention on blood
pressure control in low-income patients in Argentina: a randomized clinical
trial. JAMA. (2017) 318:1016–25. doi: 10.1001/jama.2017.11358
10. Praveen D, Patel A, Raghu A, et al. SMARThealth India: development and
field evaluation of a mobile clinical decision support system for cardiovascular
diseases in rural India. JMIR. (2014) 2:e54:1–18. doi: 10.2196/mhealth.3568
11. Magee L, Sharma S, Nathan HL, Adetoro OO, Bellad M, Goudar S, et al. The
Incidence of Pregnancy Hypertension in the Community Level Interventions
for Pre-Eclampsia (CLIP) Trials-Population-Level Data From India, Pakistan,
Mozambique, and Nigeria (Preprints with The Lancet) Available online
at: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3263650 (accessed
May 13, 2021).
12. Lassi ZS, Middleton PF, Bhutta ZA, Crowther C. Strategies for improving
health care seeking for maternal and newborn illnesses in low-and middle-
income countries: a systematic review and meta-analysis. Global Health Act.
(2016) 9:31408. doi: 10.3402/gha.v9.31408
13. Darmstadt GL, Choi Y, Arifeen SE, Bari S, Rahman SM, Mannan I,
et al. Evaluation of a cluster-randomized controlled trial of a package
of community-based maternal and newborn interventions in Mirzapur,
Bangladesh. PLoS ONE. (2010)5:e9696. doi: 10.1371/journal.pone.0
009696
14. Nagraj S, Hinton L, Praveen D, Kennedy S, Norton R, Hirst J. Women’s and
healthcare providers’ perceptions of long-term complications associated with
hypertension and diabetes in pregnancy: a qualitative study. BJOG Int J Obstetr
Gynaecol. (2019) 126:34–42. doi: 10.1111/1471-0528.15847
15. Michie S, Atkins L, West R. The Behaviour Change Wheel. A Guide to
Designing Interventions. 1st ed. Great Britain: Silverback Publishing (2014).
p. 1003–10.
16. Michie S, Van Stralen MM, West R. The behaviour change wheel: a new
method for characterising and designing behaviour change interventions.
Implement Sci. (2011) 6:42. doi: 10.1186/1748-5908-6-42
17. French SD, Green SE, O’Connor DA, McKenzie JE, Francis JJ, Michie S, et al.
Developing theory-informed behaviour change interventions to implement
evidence into practice: a systematic approach using the theoretical domains
framework. Implement Sci. (2012) 7:1–8. doi: 10.1186/1748-5908-7-38
18. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, PetticrewM. Developing
and evaluating complex interventions: the new Medical Research Council
guidance. BMJ. (2008) 337:a1655. doi: 10.1136/bmj.a1655
19. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L,
et al. CONSORT 2010 statement: extension to randomised pilot and feasibility
trials. BMJ. (2016) 355:i5239. doi: 10.1136/bmj.i5239
20. SMARThealth Pregnancy: Feasibility & Acceptability of a Complex Intervention
for High-risk Pregnant Women in Rural India. Available online at: https://
clinicaltrials.gov/ct2/show/NCT03968952 (accessed October 16, 2020).
21. World Bank Data. Available online at: http://documents1.worldbank.
org/curated/en/413031504006019846/pdf/119151-BRI-P157572-Haryana-
Gender.pdf (accessed October 16, 2020).
22. Geldsetzer P, Manne-Goehler J, Theilmann M, Davies JI, Awasthi A,
Vollmer S, et al. Diabetes and hypertension in India: a nationally
representative study of 1.3 million adults. JAMA Intern Med. (2018) 178:363–
72. doi: 10.1001/jamainternmed.2017.8094
23. Niti Aayog Data. Available online at: https://niti.gov.in/content/maternal-
mortality-ratio-mmr-100000-live-births (accessed October 16, 2020).
24. Ministry of Family Health & Welfare, Government of India. National Family
Health Survey IV, 2015-16. Available online at: https://dhsprogram.com/pubs/
pdf/FR339/FR339.pdf (accessed April 09, 2021).
25. Haryana Primary Health Centre Data. Available online at: http://
haryanahealth.nic.in/Documents/PHCsubcenter.pdf (accessed October16,
2020).
26. Andhra Pradesh Guntur District Primary Health Centre Data. Available
online at: https://pcb.ap.gov.in/Attachments%20270519/BioMedical/HcfList/
Guntur%20district.pdf (accessed October 16, 2020).
27. National Health Mission, Government of India. Anemia Mukt Bharat
Operational Guidelines. Available online at: https://anemiamuktbharat.info/
resources/ (accessed May 13, 2021).
28. World Health Organisation. Prevention and Treatment of Preeclampsia
and Eclampsia. Available online at: https://apps.who.int/iris/bitstream/
handle/10665/44703/9789241548335_eng.pdf?sequence=1 (accessed October
16, 2020).
29. Maternal Health Division, Ministry of Health & Family Welfare, Government
of India. Diagnosis & Management of Gestational Diabetes Mellitus Technical
and Operational Guidelines, 2018. Available online at: https://nhm.gov.
in/New_Updates_2018/NHM_Components/RMNCH_MH_Guidelines/
Gestational-Diabetes-Mellitus.pdf (accessed October 16, 2020).
30. Federation of Obstetric & Gynaecological Societies of India, Good Clinical
Practice Recommendations: Hypertensive Disorders of Pregnancy, 2019.
Available online at: https://www.fogsi.org/wp-content/uploads/gcpr/hdp-
fogsi-gestosis-icog-gcpr-2019.pdf (accessed October 16, 2020).
31. Nathan HL, Vousden N, Lawley E, de Greeff A, Hezelgrave NL, Sloan
N, et al. Development and evaluation of a novel vital signs alert device
for use in pregnancy in low-resource settings. BMJ Innovat. (2018) 4:192–
8. doi: 10.1136/bmjinnov-2017-000235
32. Action on Pre-eclampsia, UK. CRADLE VSA Blood Pressure Monitor.
Available online at: https://action-on-pre-eclampsia.org.uk/professional-
area/cradle-vsa-blood-pressure-monitor/#order (accessed October 16, 2020).
33. TrueHb hemometer, India. Available online at: https://www.truehb.com/
meter.php (accessed October 16, 2020).
Frontiers in Global Women’s Health | www.frontiersin.org 8 May 2021 | Volume 2 | Article 620759
Nagraj et al. SMARThealth Pregnancy: Feasibility and Acceptability
34. Open MRS Software. Available online at: https://openmrs.org (accessed
October 16, 2020).
35. Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the
framework method for the analysis of qualitative data in multi-
disciplinary health research. BMC Med Res Methodol. (2013)
13:1–8. doi: 10.1186/1471-2288-13-117
36. Rich-Edwards JW, Fraser A, Lawlor DA, Catov JM. Pregnancy
characteristics and women’s future cardiovascular health: an underused
opportunity to improve women’s health? Epidemiol Rev. (2014)
36:57–70. doi: 10.1093/epirev/mxt006
37. Gupta Y, Kapoor D, Desai A, Praveen D, Joshi R, Rozati R, et al. Conversion
of gestational diabetes mellitus to future type 2 diabetes mellitus and the
predictive value of HbA1c in an Indian cohort. Diabetic Med. (2017) 34:37–
43. doi: 10.1111/dme.13102
38. Mahalakshmi MM, Bhavadharini B, Maheswari Kumar RM, Shah SS,
Bridgette A, Choudhury M, et al. Clinical profile, outcomes, and progression
to type 2 diabetes among Indian women with gestational diabetes mellitus
seen at a diabetes center in south India. Indian J Endocrinol Metabol. (2014)
18:400. doi: 10.4103/2230-8210.131205
39. Timpka S, Stuart JJ, Tanz LJ, Rimm EB, Franks PW, Rich-
Edwards JW. Lifestyle in progression from hypertensive disorders
of pregnancy to chronic hypertension in Nurses’ Health Study II:
observational cohort study. BMJ. (2017) 358:j3024. doi: 10.1136/bmj.
j3024
40. Behrens I, Basit S, Melbye M, Lykke JA, Wohlfahrt J, Bundgaard H, et al.
Risk of post-pregnancy hypertension in women with a history of hypertensive
disorders of pregnancy: nationwide cohort study. BMJ. (2017) 2017:358.
doi: 10.1136/bmj.j3078
41. Qureshi RN, Sheikh S, Hoodbhoy Z, Sharma S, Vidler M, Payne BA, et al.
Community-Level interventions for pre-eclampsia (CLIP) in Pakistan: a
cluster randomised controlled trial. Pregnancy Hyperten. (2020) 22:109–
18. doi: 10.1016/j.preghy.2020.07.011
42. Bellad MB, Goudar SS, Mallapur AA, Sharma S, Bone J,
Charantimath US, et al. Community level interventions for pre-
eclampsia (CLIP) in India: a cluster randomised controlled trial.
Pregnancy Hyperten. (2020) 21:166–75. doi: 10.1016/j.preghy.2020.
05.008
43. Modi D, Dholakia N, Gopalan R, Venkatraman S, Dave K, Shah S, et al.
mHealth intervention “ImTeCHO” to improve delivery of maternal, neonatal,
and child care services—A cluster-randomized trial in tribal areas of Gujarat,
India. PLoS Med. (2019) 16:e1002939. doi: 10.1371/journal.pmed.1002939
44. Von Dadelszen P, Bhutta ZA, Sharma S, Bone J, Singer J, Wong
H, et al. The community-level interventions for pre-eclampsia
(CLIP) cluster randomised trials in Mozambique, Pakistan, and
India: an individual participant-level meta-analysis. Lancet. (2020)
396:553–63. doi: 10.1016/S0140-6736(20)31128-4
45. Mechael P, Batavia H, Kaonga N, Searle S, Kwan A, Goldberger A, et al.
Barriers and Gaps Affecting mHealth in Low- and Middle-Income Countries:
PolicyWhite Paper. New York, NY: The Earth Institute, Columbia University
(2010). Available online at: https://www.ghdonline.org/uploads/Barriers__
Gaps_to_mHealth_in_LMICs_-_White_Paper_-_May_2010.pdf (accessed
May 13, 2021).
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2021 Nagraj, Kennedy, Jha, Norton, Hinton, Billot, Rajan, Arora,
Praveen and Hirst. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Global Women’s Health | www.frontiersin.org 9 May 2021 | Volume 2 | Article 620759
